Arrivent Biopharma reports FY 2023 net loss of $69.3M; cash runway into 2026 after $201M IPO

ArriVent BioPharma, Inc.

R&D expenses $64.9M in 2023, up from $30.4M in 2022 on increased furmonertinib trial spending.
Net loss $69.3M vs $37.0M in prior year; cash & marketable securities $150.4M at Dec 31, 2023.
Completed $201M IPO in Jan 2024; management expects operations funded into 2026.
FDA granted Breakthrough Therapy Designation for furmonertinib in NSCLC with EGFR exon 20 ins.
Proof-of-concept data for furmonertinib in PACC mutations expected in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

ArriVent BioPharma, Inc. reported the full year ended December 31, 2023 results: net income Net loss was $69.3 million.

Period: the full year ended December 31, 2023
Net income: Net loss was $69.3 million
Result: reported results

Exact text from the filing

ArriVent BioPharma, Inc. (the “Company”) issued a press release announcing its results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

ArriVent BioPharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-040532

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.